logo
logo
MGX stock ticker logo

Metagenomi, Inc.

NASDAQ•MGX
CEO: Dr. Brian Charles Thomas Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2006-04-06
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Contact Information
5959 Horton Street, 7th Floor, EmeryVille, CA, 94608, United States
510-871-4880
www.metagenomi.co
Market Cap
$58.95M
P/E (TTM)
-0.7
17.5
Dividend Yield
--
52W High
$3.95
52W Low
$1.23
52W Range
13%
Rank39Top 39.1%
4.2
F-Score
Modified Piotroski Analysis
Based on 4-year fundamentals
Average • 4.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2022-2025

Financial Dashboard

Q4 2025 Data

Revenue

$3.91M+0.00%
4-Quarter Trend

EPS

-$0.60+0.00%
4-Quarter Trend

FCF

-$23.63M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Lead Program Shows Curative Potential MGX-001 Hemophilia A program demonstrated curative Factor VIII activity in NHPs, supporting best-in-class treatment potential.
Strategic Pipeline Reprioritization Complete Late 2025 strategic evolution focused capital on lead programs utilizing advanced genome editing capabilities for higher success probability.
Workforce Cut Extends Cash Runway Workforce reduced by 25% in Q4 2025, successfully extending anticipated cash runway into the fourth quarter of 2027.
Substantial Cash and Securities Position Cash, cash equivalents, and AFS securities totaled $160.8M as of December 31, 2025, funding near-term operations.

Risk Factors

Expect Continued Operating Losses Net loss was $87.9M in 2025; company expects increasing operating losses and requires substantial additional funding for growth.
Very Early Stage Development Hurdles Very early development efforts; company has not yet initiated clinical development for any product candidate, facing many years until potential commercialization.
Novel Technology Competitive Risks Genome editing field evolves rapidly; new technologies may discover significant advantages over current systems, materially harming business prospects.
Intellectual Property Protection Uncertain Commercial success depends on obtaining broad IP protection; patent enforcement is costly, and scope of protection remains uncertain globally.

Outlook

Advance MGX-001 Toward IND Remain on track for regulatory submission, targeting Investigational New Drug application filing in the fourth quarter of 2026 for MGX-001.
Initiate Clinical Trials in 2027 Subject to regulatory clearance, the company plans to initiate clinical trials for lead hemophilia A candidate MGX-001 during 2027.
Progress Secreted Protein Programs Leveraging MGX-001 system, evaluating AT-III deficiency applications and advancing other secreted protein deficiencies toward proof-of-concept.
Continue Ionis Collaboration Efforts Wave 1 targets (APOC3, TTR, AGT) remain in lead optimization phase, focusing on achieving protein reduction via gene knockout.

Peer Comparison

Revenue (TTM)

STRO stock ticker logoSTRO
$105.65M
-34.4%
ZNTL stock ticker logoZNTL
$26.87M
-33.8%
MGX stock ticker logoMGX
$25.21M
-51.8%

Gross Margin (Latest Quarter)

SRZN stock ticker logoSRZN
100.0%
+0.0pp
STRO stock ticker logoSTRO
100.0%
+0.0pp
TCRX stock ticker logoTCRX
71.8%
-30.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARMP$387.01M-8.270.3%198.5%
IRD$333.79M-60.7-452.3%0.0%
SRZN$222.00M-2.6-4404.2%7.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.8%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Mar 16, 2026
|
EPS:-$0.58
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data